VCCC Alliance Breast Cancer Education Series

With Dr Iris Tung and Dr Julia Dixon-Douglas

Wednesday 11 May 2022

Join a panel of experts from across the VCCC Alliance for a discussion about the new drugs changing metastatic breast cancer. Presenters will focus on new data regarding sacituzumab govitecan in triple negative breast cancer and both trastuzumab deruxtecan and tucatinib in HER2 amplified metastatic breast cancer. 

Exciting new trials in metastatic breast cancer have led to changing standard of care for patients. The CDK 4/6 inhibitors are an obvious example in oestrogen receptor positive disease in combination with endocrine therapy. Whilst we hear a lot about immunotherapy, in Australia we are still waiting to be able to use this routinely (and in a funded manner) in a subset of patients that may benefit. The “new” kids on the block are the antibody drug conjugates (drugs like T-DM1) which have shown impressive survival benefits for patients in the advanced setting. 

The VCCC Alliance Breast Cancer Education Series is targeted at a clinical audience and features open discussion about real cases and patients. While these cases are de-identified, the imagery, content and discussion can be graphic. It is not appropriate for consumer participants.

Chair

Dr Belinda Yeo

VCCC Alliance Research and Education Lead - breast cancer
Medical Oncologist, Austin Health

Presentations

ASCENT - Conquering an uphill battle in advanced triple negative breast cancer?

Dr Iris Tung

Breast Cancer Fellow, Austin Health

DESTINY is changing the treatment landscape in HER2+ breast cancer – an update on T-DXd and other novel antiHER2 therapies

Dr Julia Dixon-Douglas

Breast Cancer Trials Research Fellow, Peter MacCallum Cancer Centre

Panel

Jim Siderov AM BPharm MClinPharm BCOP AdvPracPharm FSHP  

Senior Pharmacist, Cancer Services
Austin Health